These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
294 related articles for article (PubMed ID: 10743574)
1. [Mycophenolate mofetil: a new immunosuppressive drug in dermatology and its possible uses]. Geilen CC; Orfanos-Boeckel H; Offermann G; Orfanos CE Hautarzt; 2000 Feb; 51(2):63-9. PubMed ID: 10743574 [TBL] [Abstract][Full Text] [Related]
2. Rediscovering mycophenolic acid: a review of its mechanism, side effects, and potential uses. Kitchin JE; Pomeranz MK; Pak G; Washenik K; Shupack JL J Am Acad Dermatol; 1997 Sep; 37(3 Pt 1):445-9. PubMed ID: 9308561 [TBL] [Abstract][Full Text] [Related]
3. Mycophenolic acid in dermatology a century after its discovery. Strathie Page SJ; Tait CP Australas J Dermatol; 2015 Feb; 56(1):77-83. PubMed ID: 25557632 [TBL] [Abstract][Full Text] [Related]
4. New immunosuppressive drugs in dermatology (mycophenolate mofetil, tacrolimus): unapproved uses, dosages, or indications. Assmann T; Ruzicka T Clin Dermatol; 2002; 20(5):505-14. PubMed ID: 12435521 [No Abstract] [Full Text] [Related]
8. Mycophenolate mofetil, Cellcept, a new immunosuppressive drug with great potential in internal medicine. Smak Gregoor PJ; van Gelder T; Weimar W Neth J Med; 2000 Dec; 57(6):233-46. PubMed ID: 11099793 [TBL] [Abstract][Full Text] [Related]
9. Mycophenolate mofetil and skin diseases. Hartmann M; Enk A Lupus; 2005; 14 Suppl 1():s58-63. PubMed ID: 15803935 [TBL] [Abstract][Full Text] [Related]
11. Mycophenolate mofetil: a unique immunosuppressive agent. Hood KA; Zarembski DG Am J Health Syst Pharm; 1997 Feb; 54(3):285-94. PubMed ID: 9028422 [TBL] [Abstract][Full Text] [Related]
12. Mycophenolate mofetil: new applications for this immunosuppressant. Moder KG Ann Allergy Asthma Immunol; 2003 Jan; 90(1):15-19; quiz 20, 78. PubMed ID: 12546332 [TBL] [Abstract][Full Text] [Related]
13. Mycophenolate mofetil and leflunomide: promising compounds for the treatment of skin diseases. Frieling U; Luger TA Clin Exp Dermatol; 2002 Oct; 27(7):562-70. PubMed ID: 12464151 [TBL] [Abstract][Full Text] [Related]
14. [Mycophenolate mofetil, a possible new immunosuppresant]. Weberová J; Voboril R; Semecký V Ceska Slov Farm; 2002 Sep; 51(5):220-5. PubMed ID: 12407919 [TBL] [Abstract][Full Text] [Related]
15. An analysis of the dermatological uses of mycophenolate mofetil in a tertiary hospital. George L; Hamann I; Chen K; Choi J; Fernandez-Peñas P J Dermatolog Treat; 2015 Feb; 26(1):63-6. PubMed ID: 24286467 [TBL] [Abstract][Full Text] [Related]
16. The use of mycophenolate mofetil for the treatment of autoimmune and chronic idiopathic urticaria: experience in 19 patients. Zimmerman AB; Berger EM; Elmariah SB; Soter NA J Am Acad Dermatol; 2012 May; 66(5):767-70. PubMed ID: 21783274 [TBL] [Abstract][Full Text] [Related]
18. The use of mycophenolate mofetil in liver transplant recipients. Detry O; de Roover A; Delwaide J; Meurisse M; Honoré P Expert Opin Pharmacother; 2003 Nov; 4(11):1949-57. PubMed ID: 14596648 [TBL] [Abstract][Full Text] [Related]
19. Preliminary risk-benefit assessment of mycophenolate mofetil in transplant rejection. Simmons WD; Rayhill SC; Sollinger HW Drug Saf; 1997 Aug; 17(2):75-92. PubMed ID: 9285199 [TBL] [Abstract][Full Text] [Related]
20. Mycophenolate mofetil for the management of autoimmune bullous diseases. Eskin-Schwartz M; David M; Mimouni D Dermatol Clin; 2011 Oct; 29(4):555-9. PubMed ID: 21924997 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]